REVIEWER: Mark S. Freedman, HBSc, MSc, MD, CSPQ, FANA, FAAN, FRCPC, Professor of Medicine (Neurology), University of Ottawa, Canada
Efficacy
NNT analysis
Safety
Natalizumab discontinuation studies
NeuroSens Survey on first-line orals
REVIEWER: Mark S. Freedman, HBSc, MSc, MD, CSPQ, FANA, FAAN, FRCPC, Professor of Medicine (Neurology), University of Ottawa, Canada
Efficacy
NNT analysis
Safety
Natalizumab discontinuation studies
NeuroSens Survey on first-line orals